
Opinion|Videos|September 20, 2024
Future Directions in mCRPC
Author(s)Gautam Jayram, MD, Christopher Pieczonka, MD
Panelists discuss how the treatment landscape for metastatic castration-resistant prostate cancer (mCRPC) is rapidly evolving through advancements in precision medicine and novel therapies, while emphasizing the importance of ongoing education for community oncologists to stay updated on these changes.
Advertisement
Episodes in this series

- How do you see the treatment landscape for mCRPC evolving in the coming years?
- What advice would you offer community oncologists for staying up to date with the rapidly changing field of mCRPC management?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
4
Sarah Azari, MD, on early sexual health education for women with bladder cancer
5






